Arcadia Biosciences, Inc. (RKDA) Reaches $44.45 After 4.00% Down Move; Endologix Has 1.1 Sentiment

March 15, 2018 - By Dolores Ford

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company has market cap of $341.27 million. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. It currently has negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

The stock of Arcadia Biosciences, Inc. (NASDAQ:RKDA) is a huge mover today! The stock decreased 7.38% or $3.5397 during the last trading session, reaching $44.4503. About 4.01M shares traded or 949.52% up from the average. Arcadia Biosciences, Inc. (NASDAQ:RKDA) has declined 43.32% since March 15, 2017 and is downtrending. It has underperformed by 60.02% the S&P500.The move comes after 9 months negative chart setup for the $94.86 million company. It was reported on Mar, 15 by We have $42.67 PT which if reached, will make NASDAQ:RKDA worth $3.79M less.

Analysts await Arcadia Biosciences, Inc. (NASDAQ:RKDA) to report earnings on March, 20 after the close. They expect $-2.00 EPS, up 23.08% or $0.60 from last year’s $-2.6 per share. After $-2.20 actual EPS reported by Arcadia Biosciences, Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Arcadia Biosciences, Inc., an agricultural biotechnology trait company, develops traits that enhance food, feed, and fiber crops worldwide. The company has market cap of $94.86 million. The firm offers a suite of agricultural yield traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, herbicide tolerance, and heat tolerance traits, as well as yield and agronomic trait stacks primarily for food crops, such as corn, rice, wheat, and soybean. It currently has negative earnings. It also provides agricultural product quality traits comprising gamma linolenic acid safflower oil to manufacturers of nutritional supplements, medical foods, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products.

Among 2 analysts covering Arcadia Biosciences (NASDAQ:RKDA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Arcadia Biosciences had 2 analyst reports since May 12, 2017 according to SRatingsIntel. PiperJaffray downgraded the stock to “Neutral” rating in Friday, May 12 report. The stock has “Hold” rating by Piper Jaffray on Friday, July 21.

Ratings analysis reveals 0 of Endologix’s analysts are positive. Out of 3 Wall Street analysts rating Endologix, 0 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. ELGX was included in 3 notes of analysts from September 6, 2016. The stock of Endologix, Inc. (NASDAQ:ELGX) earned “Neutral” rating by JP Morgan on Wednesday, November 16. The stock has “Hold” rating by Canaccord Genuity on Thursday, November 17. On Tuesday, September 6 the stock rating was initiated by Leerink Swann with “Mkt Perform”.

Mpm Asset Management Llc holds 2.44% of its portfolio in Endologix, Inc. for 1.12 million shares. Camber Capital Management Llc owns 8.00 million shares or 2.26% of their US portfolio. Moreover, Essex Woodlands Health Ventures Inc. has 2.03% invested in the company for 1.26 million shares. The California-based Redmile Group Llc has invested 1.44% in the stock. Senzar Asset Management Llc, a New York-based fund reported 901,541 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: